LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that a multi-center, randomized, double-masked, placebo-controlled, dose-ranging Phase 2 clinical trial to evaluate the efficacy and safety of its novel eye-drop trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension successfully achieved its primary and secondary endpoints. The data were presented at the Ophthalmology Innovation Summit in Chicago, IL. Trabodenoson was found to reduce intraocular pressure (IOP) by approximately 7 mmHg at 28 days (p< 0.001) and was safe and well tolerated with very good ocular tolerability and less eye redness (hyperemia) than currently approved glaucoma treatments.